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Abstract
Objective: To detect the early preclinical alterations in cardiac autonomic control as well as altered cardiac function in systemic 
  sclerosis (SSc) patients and their relevance to the clinical features of the disease using noninvasive methods.
Methods: 30 SSc patients and 15 healthy controls matched for age and sex underwent clinical examination, serological analysis, and 
echocardiographic assessment including Doppler flow imaging to evaluate cardiac function, and 24-hour Holter monitoring analyzed 
for arrhythmia and heart rate variability (HRV) in the time and frequency domains.
Results: The trans-mitral Doppler of early to atrial wave (E/A) ratio was reversed in five patients (16.6%) and the tricuspid E/A ratio 
was reversed in 10 patients (33.3%). Holter analysis for SSc patients revealed an increased prevalence of premature ventricular contrac-
tions (PVC) $ 10/h (P = 0.02), supra-ventricular tachycardias (SVTs) (P = 0.2), and total PVC count (P = 0.0000). Highly significant 
(P = 0.000) impairment in all HRV parameters was demonstrated in the SSc patients. Total skin thickness score (TSS), Raynaud’s phe-
nomenon and anti-scleroderma 70 (anti-SCL70) showed significant positive correlations with all arrhythmia parameters, while showing 
a significant negative correlation with the impaired ventricular diastolic function and various HRV parameters. No correlation was found 
between arrhythmia and HRV parameters and disease duration, disease type, or presence of anti-centromere antibodies.
Conclusion: Low heart rate variability, increased TSS and the presence of anti-SCL70 are correlated with preclinical cardiac involve-
ment in SSc patients and may predict the likelihood of malignant arrhythmia and sudden cardiac death. Therefore, noninvasive HRV 
evaluation before clinical cardiac involvement in these patients might be beneficial when added to the clinical and laboratory assess-
ments in detecting high-risk patients, and may allow for implementation of preventive measures and initiation of appropriate therapy 
early in the course of the disease.
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Introduction
Systemic sclerosis (SSc), a multi-systemic disorder 
of connective tissue, is characterized by widespread 
vascular abnormalities and fibrosis of the skin and 
visceral organs.1,2 Two major SSc subtypes are known, 
and these are defined according to the extent of skin 
involvement: limited cutaneous SSc (LcSSc) and dif-
fuse cutaneous SSc (DcSSc). Numerous autoantibod-
ies can be detected in the sera of SSc patients. Three 
of them are specific for SSc: anti-centromere antibody 
(ACA) in LcSSc, anti-scleroderma 70 (anti-SCL70) 
in DcSSc and anti RNA polymerase III in diffuse SSc 
with renal involvement.3
Cardiac involvement is one of the most frequent vis-
ceral complications that can affect the overall prognosis 
of the disease.4 More interestingly, heart involvement 
can occur independently from other typical complica-
tions of SSc,5 and it can be clinically occult.2
Clinically evident cardiac involvement is recog-
nized as a poor prognostic indicator. Cardio-myopathy 
with ventricular diastolic dysfunction and rhythmic 
disturbances are the most important forms, since they 
are associated with a very poor prognosis.6 The dis-
turbed rhythms may be life threatening, with sudden 
cardiac death reported in some cases of SSc.7
Increasing evidence strongly suggests that cardiac 
involvement  is  related  to  recurrent  focal  ischemic 
injury causing irreversible myocardial fibrosis.8 The 
underlying mechanism appears to be micro-  circulatory 
impairment  with  abnormal  vaso-reactivity,  the  so-
called myocardial Raynaud’s phenomenon, which is 
caused by abnormal autonomic nervous control of the 
heart.9
Autonomic dysfunction is extremely common in 
SSc, starting early in the disease process and might 
precede the development of fibrosis.10 There is a clin-
ical and experimental evidence of a link between the 
propensity for life threatening arrhythmias and sym-
patho-vagal imbalance.9
The  diagnosis  of  altered  cardiac  function  may 
sometimes be late or difficult because of the discrep-
ancies between the clinical manifestations and actual 
cardiac involvement. For this reason, early detection 
is valuable for optimal treatment and for implementa-
tion of preventive measures in the early stages of the 
disease.9 The current challenge is to detect the early 
preclinical cardiac function alterations and to   identify 
SSc patients at risk of arrhythmic complications using 
simple, noninvasive diagnostic procedures.
Heart  rate  variability  (HRV)  measurements  are 
easy to perform and noninvasive, and have good repro-
ducibility if used under standardized conditions.11,12
Changes  in  heart  rate,  and  subsequently  HRV, 
may be measured by a number of techniques. Since 
changes  in  heart  rate  and  HRV  are  autonomically 
mediated, these measurements will reflect autonomic 
nervous control of the heart. In addition, it has been 
shown that information about the general health of the 
heart, including the likelihood of malignant ventricu-
lar arrhythmias and prognostic information about sur-
vival with various cardiac diseases, may be gleaned 
from an analysis of HRV.13–15
Since a low HRV is associated with an increased 
risk for arrhythmic complications, including malig-
nant ventricular arrhythmias and sudden death, assess-
ment of patients with SSc for decreased HRV using an 
ambulatory Holter echocardiogram (ECG) recording 
might establish a method of detecting altered auto-
nomic control of the heart and predicting the resultant 
adverse outcome.15
Echocardiography assessing the left and right ven-
tricular systolic and diastolic functions of the heart 
is  a  valuable,  safe,  noninvasive  and  reproducible 
method for early detection of preclinical changes in 
cardiac function in SSc patients.16
The aim of the present study was to detect early 
preclinical changes in the cardiac autonomic control 
as well as altered cardiac functions in SSc patients, 
and their relevance to the clinical features of the dis-
ease  using  noninvasive  methods,  with  the  goal  of 
possibly implementing preventive measures and ini-
tiating therapy early in the course of the disease.
subjects and Methods
The case control study included 30 SSc patients fulfill-
ing the American College of Rheumatology classifica-
tion criteria for SSc.17 They were recruited from the 
Internal Medicine and Rheumatology Departments and 
the Rheumatology Outpatients clinic, Ain Shams Uni-
versity Hospital. They were recruited according to the 
following inclusion criteria: Age: #60 years, absence 
of heart failure on clinical examination, normal car-
diac silhouette on chest   radiography, and normal left 
ventricular systolic function on echocardiogram.Predicting early cardiac affection in patients with ssc
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We  excluded  patients  with  diabetes  mellitus  or 
other  systemic  diseases  that  could  possibly  cause 
autonomic dysfunction, myositis, arterial hyperten-
sion  and/or  renal  involvement,  atrial  fibrillation, 
atrial flutter or any other ectopic atrial rhythms that 
precluded HRV analysis, sick sinus syndrome, high 
grade  atrioventricular  (AV)  block  or  pacemaker 
rhythm, valvular heart disease and Holter recordings 
lasting less than 16 hours or with technical deficien-
cies resulting in unreliable analysis.
Fifteen healthy subjects matched for age and sex 
without known systemic, immunological or cardio-
vascular diseases and without any evidence or cause 
of autonomic neuropathies, including idiopathic Ray-
naud’s phenomenon, served as a control group.
Informed consent was obtained from each subject. 
The study was approved by the Ain Shams Medical 
Ethics Committee.
SSc  patients  were  classified  into  two  subtypes 
according to the criteria proposed by LeRoy et al19 into 
limited cutaneous SSc (LcSSc) and diffuse cutaneous 
SSc (DcSSc) groups.
All patients were subjected to the following:
•	 Full history taking with special emphasis on disease 
onset,  course  and  duration;  symptoms  of  cardiac 
rhythm disturbances (e.g. palpitations, dizziness and 
syncope); symptoms of left ventricular diastolic dys-
functions (exertional dyspnea and dyspnea at rest)
•	 A  thorough  clinical  examination  with  special 
emphasis on the extent and degree of skin involve-
ment using a modified Rodnan skin score18 where 
cutaneous thickness was assessed using a 0–3 point 
scale in 17 body surface areas (face, anterior chest, 
abdomen, and separate right and left upper arms, 
forearms, hands, thighs, fingers, legs and feet) with 
a maximum score of 51 points. The rating scale 
consisted of 0 = normal, 1 = thickened, 2 = thick-
ened and unable to pinch, and 3 = thickened and 
unable to move. The examination also checked the 
presence  of  telangiectasis,  cutaneous  calcinosis, 
cutaneous  ulcerations,  Raynaud’s  phenomenon, 
arthralgia or arthritis, and a chest examination to 
detect interstitial pulmonary fibrosis
•	 Barium meal to detect esophageal dysmotility
•	 Chest radiography to exclude patients with an 
abnormal cardiac silhouette on chest radiography 
and to detect the presence of basal fibrosis in cases 
of interstitial pulmonary fibrosis
•	 12-lead  surface  electrocardiogram  to  exclude 
patients with atrial fibrillation, atrial flutter,   ectopic 
atrial  rhythm,  sick  sinus  syndrome,    high-grade 
atrioventricular (AV) block or pacemaker rhythm.
•	 Trans-thoracic  echocardiography:  M-mode, 
2D and color Doppler flow imaging with pulsed 
and continuous wave spectral analysis of trans-
valvular flow were performed on all patients to 
assess:
•	 Segmental wall motion abnormalities,
•	 Left ventricular systolic function by M-mode 
using fractional shortening (FS) as an ejection 
phase index,20
•	 Transvalvular Doppler flow analysis was used 
to  assess  left  and  right  ventricular  diastolic 
function, where inversion of the early to atrial 
wave (E/A) wave ratio (E/A ratio , 1) of the 
trans-mitral flow was considered as an index 
of left ventricular diastolic dysfunction,20 and 
inversion of the E/A wave ratio of the trans-
  tricuspid flow was considered as an index of 
right ventricular diastolic dysfunction.1,21
•	 24  hour  ambulatory  Holter  monitoring:  All 
patients  underwent  24  hours  Holter  monitoring 
using either two- or three-channel real-time tape 
recorders (HILLMED Holter Premier IV recorder, 
HILLMED Corporation, Miami, USA) and moni-
toring of the bipolar leads CM5 and CM3 and/or 
modified augmented vector foot (aVF).
Holter tapes were analyzed using the Holter Pre-
mier IV device (HILLMED). The total number of 
ventricular  premature  beats,  presence  of  prema-
ture ventricular contractions (PVCs) $ 10/hour and 
episodes  of  non-sustained  ventricular  tachycardia 
(defined  as  $3  consecutive  ventricular  premature 
beats with a rate $100 beats/minute) were obtained 
for each patient. This monitoring was also carried out 
for the control group to determine the normal values 
of various HRV in the normal population.
heart rate variability analysis
The 24-hour HRV was assessed in both time domain 
and frequency domain after full revision of the elec-
trocardiogram and editing of beats when indicated.Othman et al
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Time domain HRV variables included:
•	 Mean RR interval (the interval between two adja-
cent QRS complexes).
•	 Standard  deviation  of  all  normal  RR  intervals 
(SDNN).
•	 Standard deviation of mean normal RR intervals 
for all five-minute segments (SDANN).
•	 Mean of the standard deviation of all normal RR 
intervals for all five-minute segments (the SDNN 
index or SDNNi).
•	 Root mean square of successive differences = the 
square  root  of  the  mean  of  the  summation  of 
squares of differences between adjacent normal RR 
intervals (rMSSD).
•	 Percentage of differences between adjacent   normal 
RR intervals greater than 50 ms (pNN50).22,23
Most time domain parameters reflect the overall 
autonomic modulation of the heart but provide no 
information  regarding  sympathetic  and  parasym-
pathetic  activity  individually,24  except  for  pNN50 
and rMSSD,12,22 which have been reported to reflect 
mostly parasympathetic activity.
Frequency domain
HRV was assessed by the auto regression parametric 
method with a spectral resolution of 0.0005 Hz using the 
Premiere IV HILLMED Holter analysis package. The 
amplitudes of the following variables were obtained:
•	 Total power (TP) = variance of all RR intervals 
(0–0.500 Hz),
•	 Very low frequency (VLF) = power in the VLF 
range (0.003–0.04 Hz),
•	 Low frequency (LF) = power in the low frequency 
range (0.04–0.15 Hz),
•	 High  frequency  (HF)  =  power  in  HF  range 
(0.15–0.4 Hz),
•	 the LF/HF ratio.22,23
Spectral  analysis  of  HRV  can  partially  separate 
parasympathetic  from  sympathetic  effects  on  the 
heart.24
HF power represents a pure vagal efferent signal 
that  is  modulated  by  ventilation  (respiratory  sinus 
arrhythmia).25,26 VLF and LF variables are thought to 
be related to the sympatho-vagal baroreflex   control 
of arterial pressure and are currently interpreted as 
an index of sympathetic activity; the LF/HF ratio can 
  provide information on the state of the   sympatho-vagal 
balance.27 High values for this ratio suggest a pre-
dominance of sympathetic nervous activity relative 
to vagal activity.26
Laboratory studies
Six milliliters of venous blood were collected from each 
subject. Two milliliters were combined with EDTA for 
a complete blood count (CBC) using the Coulter coun-
ter T660, and the erythrocyte sedimentation rate (ESR) 
following the Westergren method. Serum was collected 
from the other 4 ml in a plane tube and stored at -70 °C 
for  subsequent  assay  of  the  fasting  plasma  glucose 
level and kidney function tests (serum creatinine and 
blood urea nitrogen) using the CX5 system (Beckman 
instruments  Inc,  Minnesota,  USA),  antinuclear  anti-
bodies (ANA) were detected by indirect immunoflo-
rescence using the Kallestad kit (Bio-Rad Laboratories, 
South Africa), anti-centromere antibodies (ACA) were 
detected using the ELISA technique (anticentromere B, 
ORGENTEC, Diagnostika GmbH, Mainz, Germany), 
and serum anti-topoisomerase-1 (anti-SCL70) antibod-
ies were detected using the ELISA technique (QUANTA 
lite, Inova Diagnostics, San Diego, USA).
statistical analysis
Statistical analysis of the data was performed on an 
IBM computer using SPSS (Version 12). The mean 
and standard deviation (SD) were used to describe 
quantitative variables. Unpaired t-tests were used to 
compare quantitative variables between both groups 
while  the  Mann—Whitney—Willcoxon  u-test  was 
used  instead  of  the  t-test  in  non-parametric  data 
(SD . 50% mean). Spearman’s correlation test was 
used to rank different variables against each others 
positively or inversely. A P-value less than 0.05 was 
accepted as being statistically significant.28
Results
This case control study was carried out on 30 SSc 
patients and 15 controls.
The control group were not diabetic (normal fasting 
plasma glucose levels), having neither cause nor evi-
dence of autonomic neuropathies, and having no organic 
or structural heart disease. Their demographic, clinical, 
laboratory and Holter data are shown in Table 1.Predicting early cardiac affection in patients with ssc
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The 24-hour ambulatory Holter monitoring was 
recorded and analyzed. None of the control group had 
PVC $ 10/h, none had SVT and total PVCs counts 
were  measured  for  all.  Holter  data  were  analyzed 
for HRV parameters in both the time and frequency 
domains (Table 1).
The SSc patients consisted of 25 females (83%) 
and 5 males (17%). Their demographic clinical, labo-
ratory and Holter data re shown in Table 2.
Diffuse SSc (DcSSc) was diagnosed in 16 patients 
(53%).  Raynaud’s  phenomenon  was  present  in 
24 patients (80%), 4 patients (13%) had calcinosis, 
6 patients (20%) had telangictasis, 5 patients (17%) 
had  arthralgia,  12  patients  (40%)  had  digital  isch-
emic changes and 15 patients (50%) had sclerodactly. 
Esophageal  dysmotility  was  found  in  13  patients 
(43%) and basal pulmonary fibrosis detected by chest 
radiography was detected in seven patients (23%).
ANA  was  positive  in  28  patients  (93%),  six 
patients (20%) had positive ACA, and in 15 patients 
(50%), the anti-SCL70 titer was positive. None of 
the patients was diabetic (i.e. they had normal fasting 
plasma glucose levels) and had no renal involvement 
in any with normal serum creatinine (Table 2).
Transthoracic  echocardiography:  all  patients 
showed normal systolic function of both left and right 
ventricles with no segmental wall motion abnormali-
ties at rest. The mean overall left ventricular FS was 
32.1 ± 4.3%. Five patients (17%) had left ventricular 
diastolic dysfunction (relaxation type) with a reversed 
E/A ratio of trans-mitral color flow Doppler waves, 
while 10 patients (33%) had right ventricular diastolic 
dysfunction (relaxation type) with reversed E/A ratio 
of trans-tricuspid color flow Doppler waves (Fig. 1).
Table  1.  Demographic,  laboratory  and  holter  data  of 
  control group.
parameter Range Mean sD
Age (years)  28–46 36.1 7.8
FBs (mg/dL)  65–99 82.5 10.1
serum creatinine  
(mg/dL)
0.6–1.2 0.9 0.18
Total PVCs  
(beats per minute) 
0.0–39 12.0 11.4
Mean rr (ms)  660–1133 812.8 126.7
sDn’n (ms)  115–191 147.1 18.8
sDAnn (ms)  107–183 136.3 18.8
sDnni (ms)  36–75 61.2 12.0
rMssD (ms)  20–90 39.1 17.9
pnn50 (%)  2–27 10.3 7.9
TP (ms2)  979–5132 3150 1379
VLF (ms2) 615–3745 2171 985
LF (ms2)  236–1348 740 363
hF (ms2)  92–464 210 98
LF/hF  2.0–7.1 3.5 1.5
Abbreviations: FBs, fasting blood sugar; PVC, premature ventricular 
contractions; sDnn, standard deviation of all normal rr intervals in the 
entire 24-hr eCg recording; sDAnn, standard deviation of the mean of 
normal rr intervals for each 5-min period of the 24-hr eCg recording; 
sDnni, mean of the standard deviation of all normal rr intervals for all 
5-min segments of a 24-hr eCg recording; rMssD, root mean square 
successive difference between adjacent normal rr intervals over the 
entire  24-hr  eCg  recording;  pnn50,  percent  of  difference  between 
adjacent normal rr intervals greater than 50 ms calculated over the 
entire 24-hr eCg recording; TP, variance of all nn intervals (the interval 
between  two  successive  normal  waves);  VLF,  power  in  the  very  low 
frequency range; LF, power in the low frequency range; hF, power in the 
high frequency range; LF/hF, ratio of LF (ms2) to hF (ms2).
Table 2. Demographic, clinical, laboratory and holter data 
of systemic sclerosis patients.
parameter  Range Mean sD
Age (years)  25–50 36.8 6.5
Disease duration  
(years)
1–7 4.4 1.8
Tss (points) 3–35 14.1 7.2
FBs (mg/dL)  59–98 76.8 8.9
serum creatinine  
(mg/dL)
0.6–1.3 0.9 0.26
Left ventricular Fs (%) 26–38 32.1 4.3
Total PVCs  
(beats per minute) 
0–14468 798.7 2654
Mean rr (ms)  527–1018 685.5 113.5
sDnn (ms)  19–69 41.7 11.3
sDAnn (ms)  6–58 33.3 11.3
sDnni (ms)  10–41 22.3 7
rMssD (ms)  9–44 21.2 8.3
pnn50 (%)  0–30 4.7 5.7
TP (ms2)  86–1859 502.7 383.5
VLF (ms2) 16–1123 252.9 235.8
LF (ms2)  10–483 124.9 95.6
hF (ms2) 6.7–280 87.6 62.1
LF/hF  0.87–2.2 1.4 0.3
Abbreviations: Tss, total skin thickness score; FBs, fasting blood sugar; 
Fs,  fractional  shortening;  PVCs,  premature  ventricular  contractions; 
sDnn, standard deviation of all normal rr intervals in the entire 24-hr 
eCg recording; sDAnn, standard deviation of the mean of normal rr 
intervals for each 5-min period of the 24-hr eCg recording; sDnni, mean 
of the standard deviation of all normal rr intervals for all 5-min segments 
of  a  24-hr  eCg  recording;  rMssD,  root  mean  square  successive 
difference between adjacent normal rr intervals over the entire 24-hr 
eCg recording; pnn50, percent of difference between adjacent normal 
rr intervals greater than 50 ms calculated over the entire 24-hr eCg 
recording; TP, variance of all nn intervals; VLF, power in the very low 
frequency range; LF, power in the low frequency range; hF, power in the 
high frequency range; LF/hF, ratio of LF (ms2) to hF(ms2).Othman et al
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Figure 1. echo and eCg holter data of systemic sclerosis patients.
Abbreviations: LVDD, left ventricular diastolic diameter; rVDD, right ventricular diastolic diameter.
Table 3. Changes in the time and frequency domains of 
hrV in ssc patients and controls.
parameter ssc patients controls P
Mean sD Mean sD
sDAnn (ms) 99.3 11.3 136.3* 18.8 0.0003
sDnni (ms) 42.3 7 61.2* 12 0.0001
rMssD (ms) 12.2 8.3 35.1** 17.9 0.0003
pnn50 (%) 4.7 6 10.3** 7.9 0.0002
TP (ms2) 512.8 383.5 2640.6** 1379 0.0001
VLF (ms2) 322.8 235.8 2171.1** 984.9 0.0001
LF (ms2) 124.9 95.6 240** 163 0.0004
hF (ms2) 57.6 62.1 210.5** 97.9 0.0002
LF/hF  2.2 1.5 1.1** 0.03 0.0001
Abbreviations: sDAnn, standard deviation of the mean of normal rr 
intervals for each 5-min period of the 24 hr eCg recording; sDnni, mean 
of the standard deviation of all normal rr intervals for all 5-min segments 
of  a  24-hr  eCg  recording;  rMssD,  root  mean  square  successive 
difference between adjacent normal rr intervals over the entire 24-hr 
eCg recording; pnn50, percent of difference between adjacent normal 
rr intervals greater than 50 ms calculated over the entire 24-hr eCg 
recording; TP, variance of all nn intervals; VLF, power in the very low 
frequency range; LF, power in the low frequency range; hF, power in the 
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Figure 2. Arrhythmia in systemic sclerosis patients and controls.
24 hour ambulatory Holter monitoring: 10 patients 
(33%) had $10 PVCs/h, and SVT was present in 2 
patients  (7%)  (Fig.  1).  Total  PVC  count  and  HRV 
parameters are shown in Table 2.
On  comparing  the  results  of  Holter  monitoring 
of arrhythmia and HRV parameters in patients with 
SSc and the control group, we found a significant 
increase  in  arrhythmia  (PVCs  $  l0/h;  total  PVC 
count and presence of SVT). Within the SSc patients, 
33% had $10 PVCs/h and 7% had SVT compared 
to none in control group (P = 0.02 and 0.2 respec-
tively) (Fig. 2). The total PVC count increased from 
(12.0 ± 11.4 beats per minute) in the control group to 
(798.75 ± 2654.2 beats per minute) (P = 0.0001) in 
the SSc patients.
The parameters of the time and frequency domains 
of HRV were significantly decreased (with the excep-
tion of LF/HF which was significantly increased) in 
SSc patients compared to the controls (Table 3).
No fixed correlation was found between the various 
HRV parameters or arrhythmia and disease duration, 
disease subtypes (limited or diffuse SSc) or presence 
of ACA (Table 4).
A  significant  negative  correlation  was  found 
between various HRV parameters (with the exception 
of the LF/HF ratio, which showed a positive corre-
lation) and TSS, presence of Raynaud’s phenomenon 
and detection of anti-SCL70. On the other hand, a 
significant  positive  correlation  was  found  between 
various arrhythmia parameters and TSS, presence of 
Raynaud’s phenomenon and detection of anti-SCL70 
(Table 5).
A  significant  negative  correlation  was  found 
between various HRV parameters (with the exception 
of the LF/HF ratio, which showed a positive correla-
tion) and various arrhythmia parameters (Table 6).Predicting early cardiac affection in patients with ssc
Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 2010:3  49
A  significant  positive  correlation  was  found 
between the presence of left and/or right ventricular 
diastolic dysfunction and both TSS and anti-SCL70. 
A significant negative correlation was found between 
the presence of left and/or right ventricular diastolic 
dysfunction and various HRV parameters (with the 
exception of the LF/HF ratio, which showed positive 
correlation). A non-significant correlation was found 
between the presence of left and/or right ventricular 
diastolic dysfunction and detection of ACA (Table 7).
Table 4. Correlation between various hrV parameters and disease duration, disease subtypes and presence of ACA.
parameter ssc duration Dcssc Lcssc AcA
r P r P r P R P
Mean rr (ms) -0.34 0.010 -0.35 0.008 -0.25 0.19 -0.29 0.03
sDnn (ms) -0.08 0.560 -0.20 0.14 -0.06 0.76 -0.15 0.26
sDAnn (ms) -0.15 0.26 -0.20 0.14 -0.21 0.27 -0.14 0.30
sDnni (ms) 0.004 0.97 -0.15 0.26 0.24 0.21 -0.02 0.92
rMssD (ms) 0.11 0.42 0.07 0.58 0.13 0.39 0.01 0.95
pnn50 (%) 0.16 0.25 0.13 0.35 0.11 0.55 0.09 0.60
TP (ms2) -0.10 0.47 -0.26 0.05 0.09 0.62 0.05 0.77
VLF (ms2) -0.06 0.75 -0.21 0.11 0.17 0.38 0.08 0.65
LF (ms2) -0.11 0.41 -0.26 0.05 0.02 0.90 -0.28 0.04
hF (ms2) -0.13 0.34 -0.16 0.23 0.05 0.78 -0.07 0.59
LF/hF 0.08 0.57 -0.31 0.02 -0.08 0.66 0.009 0.99
PVCs $ 10/h -0.29 0.03 0.004 0.97 0.14 0.30 0.07 0.58
Total PVCs 0.09 0.60 -0.15 0.26 -0.21 0.11 -0.11 0.42
sVT -0.06 0.76 0.29 0.03 -0.08 0.560 0.13 0.35
Abbreviations: ssc, systemic sclerosis; Dcssc, diffuse cutaneous ssc; Lcssc, limited cutaneous ssc; ACA, anti-centromere antibody; sDnn, standard 
deviation of all normal rr intervals in the entire 24-hr eCg recording; sDAnn, standard deviation of the mean of normal rr intervals for each 5-min 
period of the 24 hr eCg recording; sDnni, mean of the standard deviation of all normal rr intervals for all 5-min segments of a 24-hr eCg recording; 
rMssD, root mean square successive difference between adjacent normal rr intervals over the entire 24-hr eCg recording; pnn50, percent of difference 
between adjacent normal rr intervals greater than 50 ms calculated over the entire 24-hr eCg recording; TP, variance of all nn intervals; VLF, power in 
the very low frequency range; LF, power in the low frequency range; hF, power in the high frequency range; LF/hF, ratio of LF (ms2) to hF (ms2); PVC, 
premature ventricular contractions; sVT, supravetricular tachycardia.
Table 5. Correlation between hrV parameters and arrhythmia, and Tss, raynaud’s phenomenon and presence of anti-
sCL70 in ssc patients.
parameter Tss Raynaud’s phenomenon Anti-scL70
r P r P r P
Mean rr (ms) -0.29 0.030 -0.35 0.008 -0.31 0.022
sDnn (ms) -0.30 0.025 -0.65 0.0003 -0.35 0.008
sDAnn (ms) -0.81 0.0002 -0.33 0.020 -0.29 0.030
sDnni (ms) -0.65 0.0003 -0.68 0.0003 -0.68 0.0003
rMssD (ms) -0.69 0.0003 -0.53 0.0004 -0.49 0.0005
pnn50 (%)  -0.49 0.0005 -0.39 0.005 -0.45 0.001
TP (ms2) -0.58 0.0004 -0.62 0.0003 -0.60 0.0003
VLF (ms2) -0.48 0.0005 -0.51 0.0004 -0.49 0.0005
LF (ms2) -0.34 0.009 -0.31 0.025 -0.27 0.040
hF (ms2)″ -0.49 0.0005 -0.52 0.0004 -0.53 0.0004
LF/hF  0.36 0.007 0.42 0.003 0.52 0.0004
PVCs $ 10/h 0.53 0.0004 0.49 0.0005 0.57 0.0004
Total PVCs 0.68 0.0003 0.39 0.005 0.78 0.0002
sVT 0.31 0.022 0.48 0.0005 0.33 0.020
Abbreviations: Tss, total skin thickness score; anti-sCL70, serum anti-topoisomerase-1; sDAnn, standard deviation of the mean of normal rr intervals 
for each 5-min period of the 24 hr eCg recording; sDnni, mean of the standard deviation of all normal rr intervals for all 5-min segments of a 24-hr eCg 
recording; rMssD, root mean square successive difference between adjacent normal rr intervals over the entire 24-hr eCg recording; pnn50, percent 
of difference between adjacent normal rr intervals greater than 50 ms calculated over the entire 24-hr eCg recording; TP, variance of all nn intervals; 
VLF, power in the very low frequency range; LF, power in the low frequency range; hF, power in the high frequency range; LF/hF, ratio of LF (ms2) to hF 
(ms2); PVC, premature ventricular contractions; sVT, supravetricular tachycardia.Othman et al
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Table 6. Correlation between hrV parameters and arrhythmia parameters in systemic sclerosis patients.
parameter pVcs $ 10/h Total pVcs sVT
r P r P r P
Mean rr (ms)  -0.36 0.007 -0.49 0.0005 -0.42 0.003
sDnn (ms) -0.28 0.033 -0.37 0.007 -0.29 0.030
sDAnn (ms) -0.40 0.005 -0.39 0.005 -0.33 0.010
sDnni (ms) -0.31 0.025 -0.50 0.0004 -0.39 0.005
rMssD (ms) -0.52 0.0004 -0.60 0.0003 -0.47 0.0005
pnn50 (%) -0.61 0.0003 -0.55 0.0004 -0.49 0.0005
TP (ms2)″ -0.66 0.0003 -0.70 0.0002 -0.70 0.0002
VLF (ms2) -0.38 0.006 -0.29 0.030 -0.28 0.033
LF (ms2) -0.26 0.050 -0.36 0.008 -0.40 0.005
hF (ms2) -0.88 0.0002 -0.51 0.0004 -0.55 0.0004
LF/hF 0.54 0.0004 0.72 0.0002 0.81 0.0002
Abbreviations: PVC, premature ventricular contractions; sVT, supravetricular tachycardia, sDAnn, standard deviation of the mean of normal rr 
intervals for each 5-min period of the 24 hr eCg recording; sDnni, mean of the standard deviation of all normal rr intervals for all 5-min segments of 
a 24-hr eCg recording; rMssD, root mean square successive difference between adjacent normal rr intervals over the entire 24-hr eCg recording; 
pnn50, percent of difference between adjacent normal rr intervals greater than 50 ms calculated over the entire 24-hr eCg recording; TP, variance of 
all nn intervals; VLF, power in the very low frequency range; LF, power in the low frequency range; hF, power in the high frequency range; LF/hF, ratio 
of LF (ms2) to hF (ms2).
Discussion
Systemic sclerosis is a multi-systemic connective tis-
sue autoimmune disorder. It is characterized by wide-
spread  vascular  abnormalities  and  fibrosis. Altered 
cardiac functions and rhythm disturbances are con-
sidered  important  prognostic  indicators,  since  they 
are associated with very poor prognosis.29
The underlying mechanism for cardiac involve-
ment  appears  to  be  micro-circulatory  impairment 
with  abnormal  vaso-reactivity,  the  so-called  myo-
cardial Raynaud’s phenomenon, which is caused by 
abnormal autonomic nervous control of the heart; the 
resultant dysrhythmia is considered one of the hall-
marks of sclerodermal heart involvement.9,30
Autonomic dysfunction is extremely common in 
SSc, starting early in the disease and possibly preced-
ing the development of fibrosis.10
Compelling evidence links sudden cardiac death 
and life threatening ventricular arrhythmia to auto-
nomic nervous system dysfunction. Increased sympa-
thetic activity appears to be pro-arrhythmic, whereas 
β-blocker therapy and enhanced parasympathetic tone 
counteract this arrhythmogenic effect. Abnormalities 
in the baseline parasympathetic tone (represented by 
reduced HRV) and in the ability to reflexively acti-
vate vagal tone (Baroreflex sensitivity) leave patients 
at a high risk for developing ventricular tachycardia 
and sudden cardiac death.9,31
The noninvasive evaluation of HRV using 24-hour 
ambulatory Holter ECG recording as a reflection of 
the autonomic control of the cardiovascular system 
might establish a reliable method for detecting altered 
autonomic  control  of  the  heart  and  predicting  any 
resultant  adverse  outcome.  Echocardiography  is  a 
valuable, safe, noninvasive and reproducible method 
for detection of early changes in preclinical cardiac 
function.4,16
This study was designed to detect the early pre-
clinical alterations in cardiac autonomic control as 
well as altered cardiac functions in SSc patients, and 
their relevance to the clinical features of the disease 
using noninvasive methods, with the goal of possi-
bly implementing preventive measures and initiating 
therapy early in the course of the disease.
In the present study, we excluded patients over 
the age of 60 years, those with clinical or radiologi-
cal heart failure, diabetic patients, patients with renal 
impairment, and patients with any kind or cause of 
autonomic dysfunction to eliminate other causes for 
arrhythmia and/or impaired HRV other than SSc.32
The  mean  disease  duration  in  our  study  was 
4.4  years.  This  relatively  short  disease  duration, 
together  with  the  tight  selection  criteria,  resulted 
in a decreased prevalence of patients with visceral 
involvement in our study in contrast to other non-
selected studies that were conducted on SSc patients. Predicting early cardiac affection in patients with ssc
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In our study, 17% of our patients had LVDD, 33% 
had RVDD, 33% had $0 PVCs/h, and 7% had SVT. 
However, in Giunta et al33 26% of their SSc patients 
had  LVDD  and  40%  had  RVDD.  In  our  patients, 
23% had pulmonary fibrosis in contrast to 48% in 
D’Andrea et al.1
Dimitroulas et al34 found impaired left and right 
ventricular diastolic function in SSc patients expressed 
by the inverted ratio of early peak to late peak trans-
mitral  flow  (E/A)  and  trans-tricuspid  velocity,  and 
increased  left  atrial  diameter  as  detected  by  tissue 
Doppler  ECG  compared  with  controls.  They  con-
cluded  that  depressed  cardiac  function  is  common 
even in asymptomatic patients with SSc.
Eighty percent of our SSc patients had Raynaud’s 
phenomenon  and  43%  had  esophageal  dysmotility. 
This high prevalence for both phenomena is attributed 
to the hypothesis that Raynaud’s phenomenon might 
represent the expression of autonomic dysfunction in 
the microcirculation.9 Esophageal   motility disorders 
have been associated with cardiac autonomic neurop-
athy. This autonomic dysfunction occurs early in the 
disease, even before the development of fibrosis, or any 
other visceral complication or manifestation.30,35,36
One-third of our SSc patients had arrhythmia in 
the form of PVC $ 10/h (33%) and SVTs (7%) in 
comparison to none of the controls. In addition, the 
number of total PVCs increased significantly in our 
patients compared to the control group.
In  a  study  by  Bielous  et  al.37  Holter  monitor-
ing of SSc patients revealed a large number of PVC 
and decreased parameters in the time and frequency 
domains relative to the controls.
These findings reflect a higher incidence of arrhyth-
mic complications and a greater propensity for sud-
den death in patients with SSc that can be explained 
by the severe impairment in autonomic control of the 
heart in SSc patients.16 This impairment in the auto-
nomic control of the heart is evidenced by the signifi-
cantly impaired HRV parameters both in the time and 
frequency domain analysis in our patients compared 
to the control group. Bienias et al16 found in his study 
that all estimated time and frequency domain values 
of HRV parameters in SSc patients were significantly 
lower than in the controls.
The maximum impairments in HRV in our SSc 
patients were found in the parameters that reflect the 
parasympathetic activity rather than those reflecting 
sympathetic or total autonomic control, in spite of 
the finding that all HRV parameters were reduced. In 
the time domain analysis, rMSSD and pNN50 were 
more affected than SDNN, SDANN and SDNNi; in 
the frequency domain analysis, the HF power was 
affected more than LF power, resulting in increase in 
the LF/HF ratio in spite of the reduction in the values 
of both LF and HF in SSc patients compared to the 
control group.
It is important to note that HRV measures fluc-
tuations in autonomic inputs to the heart rather than 
the mean level of autonomic inputs. Thus, both auto-
nomic  withdrawal  and  a  saturating  (high)  level  of 
sympathetic input lead to diminished HRV.38
Kawase  et  al39  who  demonstrated  increased 
sympathetic nerve activity and decreased parasym-
pathetic nerve activity throughout the day in SSc 
patients. In addition, Pancera et al40 found that HRV 
was reduced in patients with SSc in comparison to 
Table 7. Correlation between the presence of ventricular 
diastolic dysfunction and Tss, the presence of anti-sCL70 
and ACA in ssc patients.
parameter LVDD RVDD
r P r P
Tss 0.29 0.030 0.63 0.0003
+ve anti-sCL70 0.31 0.022 0.57 0.0004
+ve ACA 0.19 0.390 0.21 0.065
Mean rr (ms) -0.30 0.025 -0.36 0.007
sDnn (ms) -0.35 0.008 -0.29 0.030
sDAnn (ms) -0.28 0.033 -0.40 0.005
sDnni (ms) -0.26 0.050 -0.34 0.010
rMssD (ms) -0.53 0.0004 -0.68 0.0003
pnn50 (%)  -0.49 0.0005 -0.78 0.0002
TP (ms2) -0.66 0.0003 -0.82 0.0002
VLF (ms2) -0.33 0.020 -0.35 0.009
LF (ms2) -0.28 0.033 -0.26 0.050
hF (ms2) -0.55 0.0004 -0.79 0.0002
LF/hF  0.51 0.0004 0.85 0.0002
Abbreviations: Tss, total skin thickness score; anti sCL70, serum anti-
topoisomerase-1;  ACA,  anti-centromere  antibody,  sDAnn,  standard 
deviation of the mean of normal rr intervals for each 5-min period of 
the 24 hr eCg recording; sDnni, mean of the standard deviation of all 
normal rr intervals for all 5-min segments of a 24-hr eCg recording; 
rMssD,  root  mean  square  successive  difference  between  adjacent 
normal  rr  intervals  over  the  entire  24-hr  eCg  recording;  pnn50, 
percent of difference between adjacent normal rr intervals greater than 
50 ms calculated over the entire 24-hr eCg recording; TP, variance of all 
nn intervals; VLF, power in the very low frequency range; LF, power in 
the low frequency range; hF, power in the high frequency range; LF/hF, 
ratio of LF (ms2) to hF (ms2); LVDD, left ventricular diastolic dysfunction; 
rVDD, right ventricular diastolic dysfunction.Othman et al
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control subjects. On the contrary, Morelli et al41 ana-
lyzed HRV in the time domain and showed no signif-
icant difference in any variable between SSc patients 
and the controls. However, in the same study, analy-
sis of the frequency domain showed a reduction in 
HRV parameters in SSc patients in contrast to the 
controls. On the other hand, Morelli et al demon-
strated an increase in the total PVC count, the preva-
lence of frequent ventricular ectopy (PVCs $ 10/h) 
and SVT episodes in SSc patients compared to the 
controls.
To the best of our knowledge, few studies have 
evaluated  the  correlation  of  altered  HRV  and/or 
abnormal cardiac function and the subtypes, labora-
tory findings or clinical manifestation of SSc.
In the present study, we could not demonstrate any 
significant fixed correlation between thevarious HRV 
parameters or arrhythmia and disease duration, dis-
ease subtype or the presence of ACA in the sera of 
patients. These findings supported our hypothesis that 
an alteration in HRV and arrhythmia can occur early 
in the disease and in both subtypes allowing them to 
be used as markers for early assessment of altered 
cardiac function in all SSc patients.16
On  the  contrary,  Hertmosillo  et  al42  found  that 
patients  with  crest  syndrome  (LcSSc)  had  signifi-
cantly decreased parasympathetic heart rate control 
compared  to  patients  with  the  diffuse  type.  Their 
study had many important limitations, including the 
short time used for HRV analysis (only a few min-
utes) and the non-selectivity of the study population 
regarding the cardiovascular characterization during 
patient recruitment.
Our study demonstrated a significant negative cor-
relation between various HRV parameters denoting 
autonomic dysfunction and worsening of skin sclero-
sis (represented by an increased TSS score), presence 
of  microcirculatory  autonomic  dysfunction  (repre-
sented by Raynaud’s phenomenon) and the presence 
of anti-SCL70 antibodies in the sera of SSc patients. 
There  was  significant  positive  correlation  between 
the LF/HF ratio (representing sympatho-vagal imbal-
ance with sympathetic predominance) and TSS, Ray-
naud’s phenomenon and the presence of anti-SCL70 
antibodies.  This  sypmatho-vagal  imbalance  with 
sympathetic predominance provides an explanation 
for  the  positive  correlation  demonstrated  between 
various arrhythmia parameters and TSS, Raynaud’s 
phenomenon and anti-SCL70 antibodies.
The correlation of sympatho-vagal imbalance with 
the increased propensity for arrhythmic complications 
in our SSc patients was well evident in the significant 
negative correlation between HRV parameters and the 
various arrhythmia parameters. It was also supported 
by the highly significant positive correlation demon-
strated between arrhythmia and the LF/HF ratio in the 
frequency domain HRV analysis.
Ferri et al5 found a correlation between the modu-
lation of sinus node activity with a higher relative risk 
of death in older patients with circulating anti-SCL70 
antibodies.
In the present study, we found a significant positive 
correlation between subclinical deterioration of car-
diac function in SSc patients (detected by the presence 
of LVDD and/or RVDD by trans-valvular Doppler 
assessment), worsening of skin sclerosis and presence 
of anti-SCL70 antibodies in the sera of SSc patients, 
but not with the detection of ACA antibodies.
D’Andrea et al1,43 found an independent negative 
correlation between right ventricular early myocar-
dial (Em) peak velocity, Rodnan skin score and anti-
SCL70 antibodies. Nakajima et al44 found a significant 
positive correlation between ventricular diastolic dys-
function and worsening of skin sclerosis.
However, Lindqvist et al21 and Giunta et al33 found 
no  correlation  between  right  ventricular  diastolic 
dysfunction and skin involvement. In both studies, 
patient recruitment represented an important limita-
tion; both studies were conducted on SSc patients 
with  no  exclusion  criteria.  In  addition,  Lindqvist 
et al21 had only two patients (10%) with DcSSc and 
18 patients with LcSSc.
Our study demonstrated a significant negative cor-
relation between subclinical deterioration of cardiac 
function in SSc patients and various HRV parame-
ters, denoting increased sympathetic predominance 
in these patients.
Malliani et al27 and Appel et al45 observed a consis-
tently reduced HRV in patients with cardiac dysfunc-
tion characterized by signs of sympathetic activation 
such as faster heart rates and high levels of circulating 
catecholamines. A relation between changes in HRV 
and  the  extent  of  left  ventricular  dysfunction  was 
reported by Casolo et al.46Predicting early cardiac affection in patients with ssc
Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 2010:3  53
Further prospective studies may be necessary to 
assess the effect of altered autonomic control of the 
heart with sypmpathetic predominance on morbidity 
and mortality in SSc patients.
conclusion
Abnormal autonomic nervous control of the heart, 
increased TSS, and the presence of anti-SCL70 cor-
relate with subclinical cardiac involvement in SSc 
patients, and may predict the likelihood of malignant 
arrhythmia and sudden cardiac death. Therefore, non-
invasive  HRV  evaluation,  undertaken  before  clini-
cal cardiac involvement, in these patients might be 
beneficial when added to the clinical and laboratory 
assessments in detecting high-risk patients, and may 
also allow for implementation of preventive measures 
and initiation of appropriate therapy early during the 
course of the disease to prevent the deleterious effects 
on the prognosis of SSc patients.
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